Yang Wang
Directeur Technique/Scientifique/R&D chez ARRIVENT BIOPHARMA, INC.
Profil
Yang Wang is currently the Chief Technology Officer at Arrivent BioPharma, Inc. Prior to this, she held the position of Senior Director-Analytical Sciences at MedImmune LLC and Senior Vice President & Head-CMC at Viela Bio, Inc. Dr. Wang earned a doctorate degree from the University of Virginia.
Postes actifs de Yang Wang
| Sociétés | Poste | Début |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | Directeur Technique/Scientifique/R&D | 01/07/2021 |
Anciens postes connus de Yang Wang
| Sociétés | Poste | Fin |
|---|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
| VIELA BIO, INC. | Corporate Officer/Principal | - |
Formation de Yang Wang
| University of Virginia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
